Skip to main content
Premium Trial:

Request an Annual Quote

USDA, DOE Award $8M in Joint Bioenergy Genomics Grants

NEW YORK (GenomeWeb News) – The US Departments of Energy and Agriculture have jointly awarded $8 million in new grants to fund seven genomics-based projects aiming to develop domestic renewable energy sources and biofuels, USDA and DOE said yesterday.

The funding through the DOE-USDA Plant Feedstocks Genomics for Bioenergy program primarily supports studies focused on using genomics to increase the yield, quality, and adaptability of varieties of trees and grasses.

These three-year projects, which will aim to improve switchgrass, poplar, pine, and other plants, include five that received a total of $6.1 million from DOE's Office of Science and two that were awarded $2 million from USDA's National Institute of Food and Agriculture.

One award, to Jeffrey Dangl of the University of North Carolina at Chapel Hill, will provide $1.5 million for the use of genomics, genetics, and physiology to understand how endophytic bacteria alter plant growth and productivity, and whether they can be used in a predictable way to improve feedstock production.

University of Georgia investigator Katrien Devos received a $1.3 million grant to develop strategies for increasing frost tolerance in upland switchgrass and to study the potential of fungi to minimize cold stress.

University of Florida researcher Matias Kirst received $1 million to use genome-wide selection to try to speed development of loblolly and slash pines, with the aim of making them produce higher yields for energy use.

The full list of the USDA-DOE awards is available on the DOE's website.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.